efficaci
longterm
protect
recombin
felin
leukemia
viru
felv
vaccin
determin
specifi
pathogen
free
cat
year
time
order
specifi
effect
felin
immunodefici
viru
fiv
immun
system
one
half
cat
n
previous
infect
new
recombin
vaccineagainst
felin
leukemia
viru
felv
introduc
contain
felv
su
express
escherichiu
coli
marciani
et
al
first
experiment
studi
demonstr
high
efficaci
vaccin
intraperiton
challeng
exposur
clark
et
al
lehmann
et
al
marciani
et
al
field
trial
investig
safeti
seriou
system
reaction
observ
vaccin
found
safe
clark
et
al
goal
present
studi
determin
longterm
protect
singl
basic
felv
immun
use
recombin
vaccin
natur
exposur
situat
eighteen
vaccin
cat
hous
togeth
ten
felvposit
carrier
cat
year
earlier
studi
function
felin
immun
system
shortterm
felin
immunodefici
viru
fiv
infect
investig
purpos
cat
infect
fiv
zurich
fivinfect
anim
show
suppress
immun
system
earli
phase
infect
lehmann
et
al
howev
fiv
infect
lead
declin
ratio
lymphocyt
period
sever
month
year
torten
et
al
progress
clinic
stage
final
fullblown
immunodefici
syndrom
ishida
tomoda
ishida
et
al
studi
cours
outcom
fiv
felv
infect
observ
lymphocyt
subset
measur
flow
cytometri
whole
year
period
specifi
pathogen
free
spf
cat
femal
male
obtain
ciba
geigi
basel
switzerland
hous
group
two
ident
climat
room
veterinari
faculti
univers
zurich
cat
clinic
examin
weekli
blood
sampl
collect
regularli
cat
euthan
underw
detail
necropsi
histopatholog
examin
fifteen
cat
inocul
intraperiton
age
week
ml
supernat
collect
fw
zurich
infect
lymphocyt
cultur
fiv
infect
monitor
describ
lutz
et
al
detect
antibodi
enzymelink
immunosorb
assay
elisa
western
blot
viru
isol
blood
lymphocyt
twentythre
week
later
total
cat
nine
fivneg
nine
fivposit
vaccin
intramuscularli
recombin
felv
vaccin
leucogen
virbac
laboratoir
carro
nice
franc
usa
genetivac
pitmanmoor
washingtoncross
nj
twice
within
week
one
dose
vaccin
contain
su
felv
subtyp
express
eschericfzia
coli
mg
aiuminium
hydroxid
ml
adjuv
antibodi
felv
vaccin
measur
describ
lutz
et
al
elisa
use
pg
recombin
su
coat
western
blot
pg
gradient
purifi
felv
per
strip
viru
neutral
activ
determin
focusinhibit
assay
clone
cat
cell
line
lehmann
et
al
cat
felv
challeng
intraperiton
inject
week
second
vaccin
anim
receiv
ml
cell
cultur
supernat
contain
focu
form
unit
felv
subtyp
felv
infect
monitor
elisa
lutz
et
al
viru
isol
blood
bone
marrow
sampl
lehmann
et
al
western
blot
use
gradient
purifi
felv
grown
cell
theilen
et
al
felv
protein
detect
tissu
section
necropsi
anim
indirect
immunoperoxidas
assay
reinach
theilen
whole
group
cat
kept
period
year
fivneg
fivposit
anim
hous
two
separ
room
within
two
room
howev
felvneg
cat
close
contact
felv
virem
anim
imit
natur
felv
exposur
situat
revaccin
carri
flow
cytometri
lymphocyt
determin
flow
cytometri
describ
holznagel
et
al
briefli
whole
blood
sampl
defibrin
mechan
lyse
hypoton
formic
acid
indirectli
label
anti
antibodi
fluoresceinconjug
f
ab
goat
anti
mous
igg
use
secondari
antibodi
label
cell
analys
epic
profil
analyz
epic
divis
coulter
immunolog
hialeah
fl
usa
elisa
result
cell
subset
count
analys
signific
differ
mannwhitney
utest
frequenc
compar
use
fisher
exact
test
small
number
differ
consid
signific
p
sach
fivneg
fivposit
felv
vaccin
cat
develop
high
antibodi
level
felv
su
fivposit
cat
show
significantli
higher
antibodi
primari
immun
day
lehmann
et
al
increas
anti
felv
su
antibodi
vaccin
cat
six
nonvaccin
cat
intraperiton
felv
challeng
see
fig
felv
vaccin
cat
protect
persist
viremia
ten
nonvaccin
cat
becam
persist
virem
fig
two
cat
vaccin
group
two
nonvaccin
group
show
transient
viremia
result
viru
isol
viru
neutral
antibodi
assay
publish
elsewher
lehmann
et
al
cat
develop
antibodi
felv
core
protein
judg
western
blot
analysi
perform
week
challeng
infect
data
shown
prevent
fraction
pollock
scarlett
recombin
felv
vaccin
hand
calcul
year
observ
felv
challeng
exposur
anti
felv
su
antibodi
gradual
decreas
vaccin
cat
fig
signific
differ
detect
fivneg
fivposit
anim
three
year
basic
immun
specif
antibodi
vaccin
cat
drop
posit
control
includ
everi
elisa
cat
decreas
antibodi
mark
antibodi
detect
elisa
system
comparison
mean
antibodi
level
measur
felv
basic
immun
approxim
spite
low
antibodi
level
felv
neg
vaccin
cat
remain
felv
neg
throughout
whole
observ
period
fig
c
one
felv
vaccin
cat
cat
initi
felvposit
turn
neg
year
felv
nonvaccin
anim
period
increas
antibodi
felv
su
detect
data
shown
howev
infect
anim
stay
felv
antigen
elisa
posit
fig
b
sever
clinic
sign
seen
whole
observ
period
surviv
cat
anim
show
chronic
stomat
gingiv
loss
weight
experi
total
five
cat
euthan
tabl
two
fivneg
one
cat
felv
vaccin
cat
felv
vaccin
cat
suffer
lymphosarcoma
cat
special
interest
constantli
felvneg
elisa
blood
sampl
bone
marrow
cultur
lehmann
et
al
spite
fact
ill
e
io
omo
ill
ollmlloo
b
li
n
mm
fig
ad
cours
felv
infect
felv
determin
elisa
challeng
exposur
felvneg
time
death
felv
protein
detect
immunoperoxidas
assay
tissu
section
tumour
within
fivposit
group
felv
vaccin
anim
significantli
better
outcom
felv
nonvaccin
cat
respect
surviv
time
fig
clinic
iaboratori
paramet
year
coinfect
three
five
fivand
felvcoinfect
cat
euthan
apathi
sever
dehydr
bodi
temperatur
two
cat
suffer
gener
lymphaden
hyperplasia
lymphat
tissu
third
cat
addit
show
sign
septicemia
tabl
three
year
felv
challeng
exposur
mean
ratio
higher
fivand
felvneg
cat
lower
fivand
felvcoinfect
cat
fig
fivinfect
cat
significantli
lower
ratio
fivneg
cat
pmwu
ooolz
declin
ratio
fivinfect
cat
mainli
caus
low
rel
absolut
lymphocyt
count
felv
caus
decreas
ratio
within
year
infect
fivand
felvcoinfect
cat
massiv
declin
lymphocyt
found
absolut
number
reduc
minimum
cell
p
lymphocyt
strong
fluoresc
h
almost
complet
disappear
simultan
cell
distinctli
weaker
fluoresc
w
appear
fig
j
discuss
singl
basic
immun
felv
infect
use
recombin
felv
su
vaccin
protect
ten
cat
persist
viremia
period
year
increas
antibodi
felv
su
felv
challeng
exposur
found
vaccin
cat
protect
felv
viremia
boosterlik
increas
antibodi
su
explain
minim
viremia
howev
detect
two
protect
cat
western
blot
result
support
brief
viremia
exist
anim
antibodi
appear
cat
challeng
infect
independ
vaccin
viru
replic
immedi
control
immun
system
conclud
observ
antibodi
su
measur
elisa
reach
maximum
week
challeng
infect
thereaft
steadili
decreas
respect
protect
brief
period
viru
replic
may
benefici
felv
infect
antibodi
felv
su
gradual
decreas
year
follow
felv
immun
fig
protect
complet
fig
spite
live
constant
felv
challeng
situat
may
specul
humor
immun
also
cellmedi
immun
must
play
import
role
protect
found
cat
extent
cellmedi
immun
particip
whether
form
essenti
effect
protect
investig
detail
imagin
protect
prolong
felv
challeng
exposur
may
effect
similar
booster
immun
known
extent
challeng
time
exposur
import
protect
howev
feel
experiment
set
mimick
field
situat
vaccin
subsequ
challeng
exposur
one
felv
vaccin
cat
cat
expect
remain
persist
infect
felv
turn
felvneg
year
felv
challeng
exposur
fig
whether
revers
felvneg
statu
virem
phase
long
durat
frequent
field
knowledg
investig
detail
observ
howev
underlin
import
retest
felvposit
cat
even
mani
week
posit
test
genuin
chanc
anim
turn
neg
prolong
virem
phase
felv
vaccin
group
cat
supposedli
protect
felv
infect
euthan
felvpositv
lymphosarcoma
cat
never
posit
elisa
viru
isol
serum
fig
could
viru
detect
bone
marrow
week
challeng
exposur
lehmann
et
al
two
possibl
explan
develop
felvposit
lymphosarcoma
viru
protein
found
tumour
origin
brief
phase
viremia
follow
intraperiton
challeng
exposur
first
week
challeng
exposur
cat
sera
extens
examin
still
feasibl
short
period
viremia
less
week
possibl
coincid
low
viru
load
could
miss
viru
origin
spontan
infect
close
contact
felvposit
cat
time
year
follow
period
viremia
miss
interv
examin
sometim
longer
week
period
transient
increas
antibodi
recombin
su
seen
nonvaccin
felvinfect
cat
increas
antibodi
level
howev
suffici
complet
clear
viru
blood
suspect
period
correl
lower
viru
load
plasma
year
observ
uninfect
control
felvmonoinfect
anim
none
fivmonoinfect
cat
euthan
fig
observ
none
fivmonoinfect
cat
becam
sever
ill
die
within
year
particular
interest
sinc
contrast
result
ishida
et
al
found
fivinfect
anim
progress
clinic
stage
within
year
studi
howev
unknown
long
anim
infect
includ
experi
observ
fivmonoinfect
cat
remain
healthi
year
confirm
earlier
find
field
cat
lutz
et
al
healthi
fivinfect
anim
mean
age
year
fivinfect
cat
diseas
mean
age
year
conclud
incub
time
fiv
infect
field
cat
switzerland
must
least
sever
year
surviv
rate
felvinfect
cat
surprisingli
high
fig
normal
major
persist
infect
anim
die
within
year
onset
viremia
hardi
cat
studi
kept
high
hygien
etholog
standard
appar
serv
prolong
life
infect
cat
felvand
fivcoinfect
group
surviv
rate
lower
markedli
fig
three
five
cat
euthan
within
year
sinc
yet
possibl
protect
cat
reliabl
fiv
infect
complet
isol
highli
recommend
prevent
dual
felvfiv
infect
vaccin
felv
healthi
fivinfect
cat
may
vaccin
effect
recombin
felv
vaccin
lehmann
et
al
greatli
improv
clinic
outcom
increas
life
expect
depress
ratio
fivinfect
cat
mainli
due
decreas
lymphocyt
number
rel
absolut
total
lymphocyt
count
remain
less
constant
similar
result
observ
longterm
fivinfect
cat
barlough
et
al
felv
infect
lymphocyt
count
decreas
slightli
felv
noninfect
anim
ratio
remain
almost
unchang
lowest
ratio
seen
fivand
felvcoinfect
cat
due
almost
complet
loss
lymphocyt
lymphocyt
strong
fluoresc
cdgtigh
also
disappear
fig
instead
cell
distinctli
weaker
fluoresc
appear
describ
earlier
lehmann
et
al
three
possibl
mechan
could
explain
rise
cell
surfac
marker
lymphocyt
downregul
marker
mask
way
bind
antibodi
diminish
fiv
felv
infect
cell
releas
blood
stream
express
low
amount
marker
mous
larg
granular
lymphocyt
natur
killer
cell
activ
report
express
low
amount
marker
princ
et
al
sinc
character
cell
conduct
cell
identifi
interest
note
appear
cell
accompani
declin
cdghigh
lymphocyt
